Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lineage Cell Therapeutics, Inc.
Age
18–69
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) for cohorts 1,2,3
Sensorimotor incomplete, traumatic SCI (ASIA Impairment Scale B) for cohorts 4,5
Last fully preserved single neurological level (SNL) from C-4 to C-7
From 18 through 69 years of age at time of injury
Single spinal cord lesion on a post-stabilization magnetic resonance imaging (MRI) scan, with sufficient visualization of the spinal cord injury epicenter and lesion margins to enable post-injection safety monitoring
Informed consent for this protocol and the companion long term follow-up protocol must be provided and documented (i.e., signed informed consent forms) no later than 37 days following injury
Able to participate in an elective surgical procedure to inject AST-OPC1 21-42 days following SCI
You may not be if
SCI due to penetrating trauma
Traumatic anatomical transection or laceration of the spinal cord based on prior surgery or MRI
Any concomitant injury that interferes with the performance, interpretation or validity of neurological examinations
Inability to communicate effectively with neurological examiner such that the validity of patient data could be compromised
Significant organ damage or systemic disease that would create an unacceptable risk for surgery or immunosuppression
History of any malignancy (except non-melanoma skin cancers)
Pregnant or nursing women
Body mass index (BMI) \> 35 or weight \> 300 lbs.
Active participation in another experimental procedure/intervention
Clareo Health | Dose Escalation Study of AST-OPC1 in Spinal Cord Injury
